AAN 2022 | Selecting treatment options for NMOSD

Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Boston, MA, discusses factors influencing treatment selection for patients with neuromyelitis optica spectrum disorder (NMOSD). Efficacy and safety are two factors that should be considered; however, other aspects such as logistics and costs should also be presented to the patients. When selecting the most appropriate treatment for a patient, Dr Levy presents all options and factors. The patient then states their priorities – whereby, via a shared decision-making model, a conclusion is made concerning the best therapy for that individual. Since there is no formula for this process and there is rarely just one priority when choosing treatment options, a discussion between patient and clinician is of extreme relevance. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.